Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Diluted EPS of $0.18 per share (loss) for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.18 | -5.9% |
| 2023 | -$0.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.14 | -250.0% | +46.2% |
| June 30, 2025 | -$0.26 | -333.3% | -420.0% |
| March 31, 2025 | -$0.05 | -25.0% | -25.0% |
| September 30, 2024 | -$0.04 | — | +33.3% |
| June 30, 2024 | -$0.06 | — | -50.0% |
| March 31, 2024 | -$0.04 | — | — |
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -5.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2024 period, Apimeds Pharmaceuticals US, Inc.’s diluted eps has declined by 5.9% (from $0.17 per share (loss) to $0.18 per share (loss)).
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: